Author Archives: admin


Stem Cell Clinic > Articles by: admin

Stem Cell Cartilage Regeneration Market Share Analysis and Research Report by 2025 – Express Journal

By Stell Cell Research

Growth Analysis Report onStem Cell Cartilage Regeneration Market size | Industry Segment by Applications (Hyaline Cartilage, Fibrocartilage and Other), by Type (Cell Based Approaches and Non-cell Based Approaches), Regional Outlook, Market Demand, Latest Trends, Stem Cell Cartilage Regeneration Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025.Analyzes current market size and upcoming 5 years growth of this industry.

The report titled, Stem Cell Cartilage Regeneration market has adopted an organized way to evaluate the dynamics of the overall market. It provides a comprehensive Stem Cell Cartilage Regeneration market analysis comprising of a top-to-bottom research on the market dynamics, including Stem Cell Cartilage Regeneration market growth drivers, challenges, threats, and potential growth opportunities, with a key focus on not only the global market but also the regional market. In a chapter-wise format, the Stem Cell Cartilage Regeneration market share report evaluated the global supply and demand trends in the market, including the significant insights and graphical representation.

The report provides data taking into attention the latest advancements in the global Stem Cell Cartilage Regeneration Market while appraising the impact in the Stem Cell Cartilage Regeneration market of the most important players in the near future.

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/59027

Some of the Major Stem Cell Cartilage Regeneration Market Players Are:

Brief of the competitive landscape

The Stem Cell Cartilage Regeneration market report consists of a brief of the competitive terrain of this industry. The study specifies an Stem Cell Cartilage Regeneration Market analysis of the competitive scope in the competitive landscape. Data related to the participants of the industry along with its current share in the Stem Cell Cartilage Regeneration market, area served as well as production sites is involved in the report.

Along with that, details regarding companys product portfolio, products application areas, as well as features of the product has been presented in the research study of Stem Cell Cartilage Regeneration Market report. Information about the profiles of the companies as well as data related to their profit margins and models is also induced in the report.

Stem Cell Cartilage Regeneration Market Outlook by Applications:

Stem Cell Cartilage Regeneration Market Statistics by Types:

The research report studies the historical, present, and future performance of the Stem Cell Cartilage Regeneration market. The report further evaluates the present competitive landscape, prevalent business models and the possible advancements in offerings by significant players of Stem Cell Cartilage Regeneration market in the up-coming years.

Key highlights of the Stem Cell Cartilage Regeneration market report:

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/59027

Read more:
Stem Cell Cartilage Regeneration Market Share Analysis and Research Report by 2025 - Express Journal

Global Tissue Engineering Market (2019 to 2027) – Analysis and Forecasts by Tissue Type, Application and Geography – ResearchAndMarkets.com – Business…

By Stell Cell Research

DUBLIN--(BUSINESS WIRE)--The "Tissue Engineering Market to 2027 - Global Analysis and Forecasts by Tissue Type; Application, and Geography" report has been added to ResearchAndMarkets.com's offering.

The tissue engineering market was valued at US$ 9,529.21 million in 2019 and is expected to grow at a CAGR of 13.5% from 2020 to 2027 to reach US$ 25,586.55 million by 2027.

Driving factors of the tissue engineering market are increasing incidences of chronic diseases, road accidents, and trauma injuries, as well as technological advancements in the field of 3D tissue engineering. However, high cost of treatments related to tissue engineering is expected to restrain the growth of the market during the forecast period.

Rising incidence of chronic diseases and growing number of trauma injuries and road accidents are prime factors contributing to the growth of the market for advanced treatment procedures, such as tissue engineering. Road accidents are among the major fatalities worldwide as they cause serious injuries to bones and organs. As per the WHO, ~20-50 million people get injured every year in road accidents. Tissue engineering offers alternatives to surgical reconstruction, transplantation, and mechanical device instruction to repair damaged tissues. The tissue engineering market is mainly driven by a continuous need for effective regenerative treatments to treat increasing cases of diabetes, obesity, and other disorders caused by lifestyle changes; growing base of elderly people; and rising number of trauma cases.

Moreover, the increasing government funding for research activities is expected to enhance the growth of the tissue engineering market. For instance, as per the National Institutes of Health (NIH) funding study in the US, the research studies pertaining to stem cell and regenerative medicines received funding of USD 1.8 billion and USD 1.0 billion, respectively, in 2018.

The global tissue engineering market is segmented into material type and application. The tissue engineering market, by material type, is further segmented into synthetic material, biologically derived materials, and others. The biologically derived materials segment held the largest share of the market in 2019, whereas the segment synthetic materials is anticipated to register the highest CAGR in the market during the forecast period. Based on application, the market is further segmented into orthopedic, musculoskeletal, and spine; neurology; cardiology and vascular; skin; and others. The orthopedic, musculoskeletal, and spine segment held the largest share of the market in 2019, whereas the skin segment is estimated to register the highest CAGR in the market during the forecast period.

Some of the essential primary and secondary sources included in the report are Centers for Disease Control and Prevention, Food and Drug Administration, and Organization for Economic Co-operation and Development.

Reasons to Buy:

Market Dynamics

Drivers

Restraints

Opportunities

Trends

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/izu0dk

Read more:
Global Tissue Engineering Market (2019 to 2027) - Analysis and Forecasts by Tissue Type, Application and Geography - ResearchAndMarkets.com - Business...

Stem Cell Market Competitive Insights and Research 2020 Cole Reports – Cole of Duty

By Stell Cell Research

Global Stem Cell Market Research Report published bymarket insight reportsexplores the current outlook in global and key regions from the perspective of Major Players, Countries, Product types and end industries. This report analyzes top players in the global market, and divides the Market into several parameters.

This Stem Cell Market research report identifies the competitive landscape of industries to understand the competition at International level. This report study describes the projected growth of the global market for approaching years from 2019 to 2027. This research report has been aggregated on the basis of static and dynamic aspects of the businesses.

Click Here to Get Sample PDF Copy of Latest Research on Stem CellMarket 2019:

https://www.marketinsightsreports.com/reports/03121899392/global-stem-cell-market-research-report-2015-2027-of-major-types-applications-and-competitive-vendors-in-top-regions-and-countries/inquiry?Mode=18

The prominent players in the Global Stem Cell Market:

Cyagen Biosciences, Cellular Biomedicine, Xian International Medical Investment Co., Ltd., Guanhao Biotech Co.,Ltd., Sichuan Languang Development Co.,Ltd., Shire Life Group, Anhui Lejin Health Technology Co., Ltd., Stemedica, Hebei Life Origin Biotechnology Co., Ltd., Zhongyuan Concord Cell Genetic Engineering Co., Ltd., Cordlife and Others.

It further provides the profile reviews of the leading participants, their overall market shares in the global market, business strategies they have adopted, and the latest developments in their respective business in a bid to enhance the decision-making capability of the readers.

The Stem Cell market can be divided based on product types and Its sub-type, major applications and Third Party usage area, and important regions.

This report segments the Global Stem Cell Market on the basis ofTypesare:

Allogenic SCsAutologous SCs

On the basis ofApplication,the Global Stem Cell Market is segmented into:

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOthers

SPECIAL OFFER: AVAIL UPTO 20% DISCOUNT ON THIS REPORT:

https://www.marketinsightsreports.com/reports/03121899392/global-stem-cell-market-research-report-2015-2027-of-major-types-applications-and-competitive-vendors-in-top-regions-and-countries/discount?Mode=18

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), and market share and growth rate of Stem Cell Market these regions, from 2019 to 2027 (forecast), coveringNorth America, Europe, China, Japan, Southeast Asia, India, North America(USA, Canada and Mexico)Europe(Germany, France, UK, Russia and Italy)AsiaPacific(China, Japan, Korea, India and Southeast).

Detailed overview of Stem Cell Market Changing market dynamics of the industry In-depth market segmentation by Type, Application etc. Historical, current and projected market size in terms of volume and value Recent industry trends and developments Competitive landscape of Stem Cell Market Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth

The research includes historic data from 2014 to 2019 and forecasts until 2027 which makes the report an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts and stakeholders looking for key industry data in readily accessible documents with clearly presented tables and graphs.

Finally, the Stem Cell market report offers a complete and detailed study of global Stem Cell market by using numerous analytical tools and models such as SWOT analysis, investment return analysis, and porters five forces analysis which are useful for beginners to access the upcoming opportunities. After exploring the market insights through primary and secondary research methodologies, if anything is required except than this, market insight reports will provide customization as per specific demands.

Click the link to Purchase This Full Report @:

https://www.marketinsightsreports.com/report/purchase/03121899392?mode=su?Mode=18

We also offer customization on reports based on specific client requirement:

1- Freecountry level analysis forany 5 countriesof your choice.

2-FreeCompetitive analysis ofany 5 key market players.

3-Free40 analyst hoursto cover any other data points.

Note: All the reports that we list have been tracking the impact of COVID-19 the market. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

Read this article:
Stem Cell Market Competitive Insights and Research 2020 Cole Reports - Cole of Duty

OncoImmune Starts Phase III Clinical Trial Testing the Power of Dampening Inflammation to Virus-induced Cellular Injury in Severe COVID-19 Patients |…

By Stell Cell Research

DetailsCategory: AntibodiesPublished on Wednesday, 22 April 2020 10:00Hits: 146

ROCKVILLE, MD, USA I April 21, 2020 I OncoImmune, Inc. initiated its Phase III clinical trial testing the safety and efficacy of CD24Fc in hospitalized COVID-19 patients (SAC-COVID) at the University of Maryland Baltimore Medical Center on April 20, 2020. The national trial will involve at least 10 medical centers throughout the nation. Dr. Shyamasundaran Kottilil, Professor of Medicine, Director, Division of Clinical Care and Research at the Institute of Human Virology at the University of Maryland School of Medicine is the Principal Investigator of the trial and Dr. Joel Chua, Assistant Professor of Medicine, Division of Clinical Care and Research, Institute of Human Virology at the University of Maryland School of Medicine is the clinical principle investigator for the University of Maryland Medical Center. ClinSmart, LLC of Newton, Pennsylvania is the Clinical Research Organization contracted to manage the trial.

The new trial will test the impact of OncoImmunes flagship product, CD24Fc, in dampening inflammation caused by virus-induced cellar injuries, which is likely a major underlying cause of cytokine storm, immune dysfunction and pneumonia observed in severe COVID-19 patients. A cohort of 230 subjects with severe clinical symptoms will be randomized and administered a single dose of CD24Fc (480 mg by IV infusion) or placebo and followed over a 28-day period to assess safety and efficacy in clinical improvement. As the drug has a novel mechanism of action, it will likely synergize with other drugs, including antiviral treatments such as chloroquine and Remdesivir, or other immune modulators targeting cytokines or their receptors. Therefore, the trial will accept patients undergoing, or intending to enroll in trials testing other experimental therapies.

OncoImmune is grateful to Dr. Kottilil and the University of Maryland Baltimore for leading the clinical effort, said Martin Devenport, the Chief-operating Officer of OncoImmune. It took only 12 days from FDA approval to get the trial started and we could not have achieved this without the dedicated staff from the University and the CRO, added Raymond Touomou, Vice President for Clinical Operations.

About OncoImmune, Inc.

OncoImmune (www.oncoimmune.com) is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel immunotherapies for cancer, inflammation and autoimmune diseases. OncoImmune is based in Rockville, Maryland.

OncoImmunes lead product, CD24Fc, is a novel therapeutic that regulates host inflammatory response to tissue injuries and which has broad implications in the pathogenesis of cancer, autoimmune disease, metabolic syndrome and graft-versus-host disease (GVHD). CD24Fc has completed a Phase IIa trial for the prophylactic treatment of acute GVHD in leukemia patients undergoing hematopoietic stem cell transplantation (HSCT) and resulted in a significant improvement in 180 Day Grade III-IV acute GVHD Free Survival, the Phase III primary endpoint. CD24Fc prophylaxis also resulted in reduced relapse and, compared to match controls, CD24Fc demonstrated improvement in Overall Survival, Non-Relapse Mortality and Relapse-Free Survival. A dose-dependent reduction in severe (Grade > 3) mucositis was also observed. A 20 patient open label dose expansion cohort at the recommended clinical dose is fully enrolled and the drug continues to perform very well. A Phase III study for the prevention of acute GVHD is anticipated to start in mid-2020.

SOURCE: OncoImmune

See the article here:
OncoImmune Starts Phase III Clinical Trial Testing the Power of Dampening Inflammation to Virus-induced Cellular Injury in Severe COVID-19 Patients |...

Research Antibodies Market Global Opportunity Analysis and Forecast 2018-2028 Cole Reports – Cole of Duty

By Stell Cell Research

Global Research Antibodies Market: Overview

The global research antibodies market is predicted to be a progressive one over the forecast period. The exceptional physiological properties of antibodies make them sought-after for cell research. Antibodies have the ability to bind to specific molecules, which allows molecules of interest to be isolated for cell research. This is a key factor for continual research to study the anatomy and physiology of antibodies.

Order Brochure for more Detailed Information @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=4440

The report serves readers to gauge prevailing trends and future growth opportunities in the global research antibodies market. It comprises the most relevant data pertaining to market dynamics. A detailed analysis of the competitive landscape is a key feature of the report.

Global Research Antibodies Market: Key Trends

At present, the number of R&D activities carried out by pharmaceutical and biopharmaceutical companies to introduce novel products is on the rise. These pursuits involve the use of antibodies that exhibit exceptional physiological properties. This, in turn is boosting research on antibodies for their use for secondary cell research.

Hefty investments from pharmaceutical giants for advancement of antibodies research is also boosting the research antibodies market.

Furthermore, increasing incidence of cancer and other chronic diseases is encouraging research organizations and pharmaceutical and biotechnology companies to develop advanced therapeutics and personalized medicine. The use of antibodies for early detection of cancer is also increasingly recognized. These factors collectively are stimulating the research antibodies market.

Besides this, increasing public and private initiatives and adequate funds for stem cell research are aiding the growth of research antibodies market.

Request TOC for Facts & Tables @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=4440

Global Research Antibodies Market: Market Potential

In a new development, the FDA has approved the clinical use of DNA-encoded monoclonal antibody (DMAb) therapy to prevent Zika virus infection. Unlike conventional therapeutic antibodies manufactured in industrial units, DMAb employed for the therapy is made inside the body. Patients are administered DNA instructions for the body to equip itself with necessary tools, and make its own highly specific antibodies to fight infection. The antibodies produced fight pathogenic targets such as virus-infected cells, bacteria, and cancer cells.

DMAb therapy is bringing about a clinical change in antibody therapy. Over the recent past, detailed preclinical studies using DMAb have been conducted, resulting in successful in vivo production of DMAb. The new approach displays extensive potential for major advancement over traditional monoclonal antibody therapy. Further, DMAb therapy could broaden the spectrum of antibody therapeutics, thereby opening new patient markets for antibody-based therapies for disease prevention or treatment.

Global Research Antibodies Market: Regional Outlook

North America holds supremacy among the key regions for research antibodies globally. Presence of a large number of biopharmaceutical and biotechnology companies coupled with immense government support for research are key factors behind the growth of North America research antibodies market. In addition, manufacturers of antibodies need to adhere to stringent guidelines for high quality products. This provides enhance reliability for researchers and clinicians involved in antibodies research and secondary cell research.

Asia Pacific is expected to display remarkable growth in the research antibodies market over the forecast period. Increasing R&D and adoption of novel techniques for antibodies production is serving to boost this region. Furthermore, improving healthcare infrastructure and implementation of stringent quality adherence policies by public organizations in emerging economies is spurring growth of Asia Pacific research antibodies market.

Global Research Antibodies Market: Competitive Landscape

Some key companies operating in the global research antibodies market are Abcam PLC, Thermo Fisher Scientific Inc., and Agilent Technologies. Top companies in the market are adopting novel growth strategies to sustain the highly competitive environment.

Avail the Discount on this Report @https://www.tmrresearch.com/sample/sample?flag=D&rep_id=4440

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Visit link:
Research Antibodies Market Global Opportunity Analysis and Forecast 2018-2028 Cole Reports - Cole of Duty

Induced Pluripotent Stem Cells Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 – Surfacing Magazine

By Induced Pluripotent Stem Cells

DataIntelo report titled Global Induced Pluripotent Stem Cells Market provides detailed information and overview about the key influential factors required to make well informed business decision. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Our data has been culled out by our team of experts who have curated the report, considering market-relevant information. This report provides latest insights about the markets drivers, restraints, opportunities, and trends. It also discusses the growth and trends of various segments and the market in various regions.

Request Free Sample Report of Induced Pluripotent Stem Cells Market Report @ https://dataintelo.com/request-sample/?reportId=77310

Induced Pluripotent Stem Cells Market Report Includes:

For More Information on This Report Visit @ https://dataintelo.com/enquiry-before-buying/?reportId=77310

By Product Types:HepatocytesFibroblastsKeratinocytesAmniotic CellsOthers

The report is further broken down into various segments such as product types, applications, and regions.

By Applications:Academic ResearchDrug Development And DiscoveryToxicity ScreeningRegenerative Medicine

Our analysts drafted the report by gathering information through primary (through surveys and interviews) and secondary (included industry body databases, reputable paid sources, and trade journals) methods of data collection. The report encompasses an exhaustive qualitative and quantitative evaluation.

The study includes growth trends, micro- and macro-economic indicators, and regulations and governmental policies.

By Regions:Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

The Induced Pluripotent Stem Cells Market Report Covers the Following Companies:Fujifilm Holding CorporationAstellas PharmaFate TherapeuticsBristol-Myers Squibb CompanyViaCyteCelgene CorporationAastrom BiosciencesAcelity HoldingsStemCellsJapan Tissue EngineeringOrganogenesis

The subject matter experts analyzed various companies to understand the products and/services relevant to the market. The report includes information such as gross revenue, production and consumption, average product price, and market shares of key players. Other factors such as competitive analysis and trends, mergers & acquisitions, and expansion strategies have been included in the report. This will enable the existing competitors and new entrants understand the competitive scenario to plan future strategies.

To Purchase This Report: https://dataintelo.com/checkout/?reportId=77310

The Report Provides:

The Induced Pluripotent Stem Cells Market Report Addresses the Following Queries:

For Best Discount on Purchasing this Report Visit https://dataintelo.com/ask-for-discount/?reportId=77310

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: sales@dataintelo.comWebsite: https://dataintelo.com

Read more:
Induced Pluripotent Stem Cells Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 - Surfacing Magazine

Induced Pluripotent Stem Cells Market 2019 analysis, size, top companies, share, strategies and forecast to 2026 – WhaTech Technology and Markets News

By Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells Market research report provides the details about Industry Chain structure, Market Competition, Market Size & Share, SWOT Analysis, Technology, Cost, Raw Materials, Consumer Preference, Development & Trends, Regional Forecast, Company & Profile, and Product & Service.

This Induced Pluripotent Stem Cells Market research report is focused on providing its reader with all the necessary details that can help them make necessary business decisions. It provides wholesome information that is necessary to understand the market inside-out.

ReportsnReports has recently added a new research report to its expanding repository. The research report, titled Induced Pluripotent Stem Cells Market, mainly includes a detailed segmentation of this sector, which is expected to generate massive returns by the end of the forecast period, thus showing an appreciable rate of growth over the coming years on an annual basis.

The research study also looks specifically at the need for Induced Pluripotent Stem Cells Market.

Download A Sample Report atwww.reportsnreports.com/contactme=2906851

Report Scope:

This study is focused on the market side of iPSCs rather than its technical side. Different market segments for this emerging market are covered.

For example, application-based market segments include academic research, drug development and toxicity testing, and regenerative medicine; product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation and cell analysis; iPSC-derived cell-type-based market segments include cardiomyocytes, hepatocytes, neurons, endothelia cells and other cell types; geography-based market segments include the U.S., Europe, Asia-Pacific and Rest of the World.

Research and market trends are also analyzed by studying the funding, patent publications and research publications in the field.

Report Includes:

59 tables

An overview of the global market for induced pluripotent stem cells

Analyses of global market trends with data from 2018 and 2019, and projections of compound annual growth rates (CAGRs) through 2024

Information on induced pluripotent stem cell research products, including various assays and kits, culture media and medium components, such as serum, growth factors and inhibitors, antibodies, enzymes

Complete understanding of the key technologies adopted for induced pluripotent stem cell research

Discussion of important manufacturers, technologies, and factors influencing market demand, such as the driving forces and limiting factors of induced pluripotent stem cell market growth

Profiles of major players in the industry, including Applied StemCell Inc., BlueRock Therapeutics, Corning Life Sciences, EMD Millipore, Lonza Group Ltd., Promega Corp. and Thermo Fisher Scientific Inc.

Summary

It has been over 10 years since the discovery of induced pluripotent stem cell (iPSC) technology. The market has gradually become an important part of the life sciences industry during recent years.

Particularly for the past five years, the global market for iPSCs has experienced a rapid growth. The market was estimated at REDACTED in 2018 and over REDACTED in 2019, with an average REDACTED growth.

The overall iPSC market is forecast to continue its steady growth and reach REDACTED in 2024, with anestimated compound annual growth rate (CAGR) of REDACTED from 2019 through 2024.

Key Drivers for Market Growth

This report has identified several key drivers for the rapidly growing market

iPSCs hold promising hope for therapeutic solutions for diseases without ethical issues. A series of technical breakthroughs were made in recent years for improving cellular reprogramming, differentiation and large-scale production of GMP- grade iPSCs derived cells toward clinical usability.

Advances in genetics such as NGS technologies have promoted the progress on precision medicine, where the availability of iPSCs from a variety of genetic, lifestyle and environment backgrounds will help make the precision healthcare a clinical reality. iPSC banking together with related technologies is developing into a platform for precision and personalized medicine, which is experiencing rapid growth globally.

In recent years, several iPSCs clinical trials have been or are going to be launched for a variety of diseases. The first human iPSC clinical trial started in August 2014, and the recent report of the first macular degeneration patient treated with the sheets of retinal pigmented epithelial cells made from iPSCs was encouraging.

The progresses toward clinical practice will drive the growth of the clinical market and the research market as well.

The pharmaceutical industry needs better cell sources such as iPSC-derived functional cells for drug toxicity testing and drug screening.

The U.S. government has been encouraging the marketing of stem cells, including iPSCs.

The U.S. Food and Drug Administration (FDA) has been authorized to provide orphan drug designations for many of the therapies developed for rare diseases such as Parkinsons and Huntingtons using stem cells.

The provisions of grants from organizations, such as the National Institutes of Health (NIH) and the California Institute for Regenerative Medicine (CIRM) have been encouraging for the research institutes to venture into iPSC research.

Rapidly growing medical tourism and contract research outsourcing drives the Asia-Pacific stem cell market.

Cellular reprogramming, including iPSC technology, was awarded the 2012 Nobel Prize.

New biotechnologies such as CRISPR/Cas genome editing technology are advancing iPSCs into more and better uses. For example, the hypoimmunogenic derivatives of engineered iPSCs have shown lost immunogenicity which would become a potential novel therapy to treat various diseases.

Please Share Your Specific Interest To Serve You Better | Download PDF Brochure atwww.reportsnreports.com/contactme=2906851

Recent Industry Trend:

The report contains the profiles of various prominent players in the Global Induced Pluripotent Stem Cells Market. Different strategies implemented by these vendors have been analyzed and studied in order to gain a competitive edge, create unique product portfolios and increase their market share.

The study also sheds light on major global industry vendors. Such essential vendors consist of both new and well-known players.

In addition, the business report contains important data relating to the launch of new products on the market, specific licenses, domestic scenarios and the strategies of the organization implemented on the market.

Scope of the Report:

Through following the Induced Pluripotent Stem Cells Market through depth, the readers should find this study very helpful. The aspects and details are depicted by charts, bar graphs, pie diagrams, and other visual representations in theInduced Pluripotent Stem Cells Market study.

This intensifies the representation of the pictures and also helps to improve the facts of the Induced Pluripotent Stem Cells Market industry. At a substantial CAGR, the Induced Pluripotent Stem Cells Market is likely to grow.

Induced Pluripotent Stem Cells Market reports main objective is to guide the user to understand the market in terms of its definition, classification, industry potential, the latest trends, and the challenges facing the Induced Pluripotent Stem Cells Market.

Access Full Report atwww.reportsnreports.com/purchasme=2906851

And More

This email address is being protected from spambots. You need JavaScript enabled to view it.

Original post:
Induced Pluripotent Stem Cells Market 2019 analysis, size, top companies, share, strategies and forecast to 2026 - WhaTech Technology and Markets News

The Best Face and Body Skin-Care Products for 2020 – Shape Magazine

By Platelet Rich Plasma Injections

When our panelists were asked which innovation showed the best results, scalp injections of platelet-rich plasma (PRP) for hair growth was at the top of many lists. You get significant benefits with very little downside, Dr. Schultz says. First, your blood is drawn and spun in a centrifuge to separate the PRP, which is then injected all over your scalp. Using your bloods growth factors to stimulate collagen and follicles lets your own body work its magic, says dermatologist Mona Gohara, M.D.

Another new option is a laser called Lutronic KeraLase ($750 to $1,000 per treatment), which is paired with a synthetic growth factor serum. The device stamps across your scalp, stimulating the area and creating tiny channels in the follicles, where the serum is then applied. It delivers active ingredients where theyre needed, says dermatologist Jeanine Downie, M.D. The serum can contain even more growth factors than a persons own PRP, plus stem cells to help hair growth, she says. Nutrafol for Women (Buy It, $79 $88 for 1 month, nutrafol.com), a supplement brand for hair loss, also garnered multiple mentions from our panel. Ive seen promising results, especially in conjunction with the above treatments, Dr. Downie says.

Read the original post:
The Best Face and Body Skin-Care Products for 2020 - Shape Magazine

Stem Cell Therapy: A Promising Treatment for COVID-19? – Technology Networks

By Stem Cell Medical Center

Stem cell therapy is making its way into COVID-19 treatment. Its use seems to be particularly efficient in the case of severely ill patients, as demonstrated by a study conducted at the Beijing YouAn Hospital recently published in the peer reviewed journalAging and Disease, and as emerged after the press conference hold by Sun Yanrong, deputy head of the China National Center for Biotechnology Development under the Ministry of Science and Technology.Bioscience Institute a company specializing in stem cell isolation, expansion and cryopreservation reported the results of the Beijing study on the diseases associated with novel coronavirus (SARSCoV-2) infection as they were anticipated before their publication. Now its authors confirm that The intravenous transplantation of MSCs [Mesenchymal Stem Cells] was safe and effective for treatment in patients with COVID-19 pneumonia, especially for the patients in critically severe condition. And according to Sun Yanrong, stem cell treatment has already been used in more than 200 cases in the most affected city in China, Wuhan.Stem cell treatment: how it worksStem cell treatment efficacy lies on the immunomodulatory effect of stem cells. In particular, as emerged from theAging and Diseasestudy, MSCs may help counteract the so-called cytokine storm, an uncontrolled rise of the immune response resulting in the increase of inflammation mediators (cytokines).

During a cytokine storm the immune system goes into overdrive and the patient's tissues and organs can be fatally damaged. Acute respiratory distress syndrome (ARDS) is a common sign of a cytokine storm. In COVID-19 patients it corresponds to the severe oxygen deprivation that requires mechanical ventilation.

Cytokine storm seems to be a good target for severe COVID-19 cases treatment. Nowadays, other drugs, such as tocilizumab, act on this phenomenon. In particular, tocilizumab has already been approved both in China and the USA for the treatment of severe COVID-19 and is used in clinical trials in Europe.Stem cells against COVID-19: beyond ChinaStem cell treatment has already crossed Chinas borders too. A few days before Sun Yanrong pressconference, the US Food and Drug Administration (FDA) opened the way to the compassionate use ofMSCs intravenous infusions in patients with COVID-19 ARDS and a very dismal prognosis.

There are lots of clinical trials that explored, or are planning to explore, immunomodulatory andanti-inflammatory properties of MSCs, Giuseppe Mucci, CEO of Bioscience Institute, highlights.

Cytokines are important mediators of the inflammatory process, and MSCs are believed toregulate their production. In particular, they seem to be involved in the downregulation ofproinflammatory cytokines and in the upregulation of anti-inflammatory cytokines. Their use issafe, and studies in larger cohorts of patients will validate their benefits.

Bioscience Institute is ready to contribute to this validation. We are working on a protocol for aMSCs treatment with stem cells isolated and expanded at our facilities. With our long-standingexperience in the field of stem cells isolation, expansion and cryopreservation, Bioscience Institutelaboratories are among the most advanced in the world.

Compassionate use of MSCs approved by FDA will utilize allogeneic (from a donor) stem cells.However, anyone can build up its own MSCs reserve. They can be easily obtained from severaltissues, but fat is considered the best source ever, Mucci explains. To obtain the huge cellnumbers needed for COVID-19 treatment it is fundamental MSCs expansion. That is why it is notsufficient to rely on a cell bank: only a cell factory like Bioscience Institute is able to guarantee thebanking of a quantity of MSCs useful for such a treatment.

More:
Stem Cell Therapy: A Promising Treatment for COVID-19? - Technology Networks

Israeli COVID-19 treatment with 100% survival rate tested on US patient – The Jerusalem Post

By Stem Cell Medical Center

Israeli-based Pluristem has treated its first American patient suffering from COVID-19 complications under the countrys compassionate use program.The news comes days after a report by the company showed that six critically ill coronavirus patients in Israel who are considered high-risk for mortality were treated with Pluristems placenta-based cell-therapy product and survived, according to preliminary data provided by the Haifa-based company.In the US case, the patient was treated with the companys PLX cell therapy at Holy Name Medical Center in New Jersey, where Pluristem is already running a Phase III critical limb ischemia study. Like the patients treated in Israel, this patient was critically ill with respiratory failure due to acute respiratory distress syndrome and was intubated in an intensive care unit for three weeks.The companys president and CEO, Yaky Yanay, said that although Pluristem is focused on a planned multinational clinical trial for the treatment of complications associated with coronavirus, it does hope to expand treatment under compassionate use in other countries at the same time.

Specifically, the US treatment was administered under the US Food and Drug Administrations Single Patient Expanded Access Program, which is part of the US Coronavirus Treatment Acceleration Program - an emergency program aimed at getting treatments to corona patients as quickly as possible.

In Israel, the six patients were treated at three different Israeli medical centers for one week, also under a compassionate use program. They were suffering from acute respiratory failure and inflammatory complications associated with COVID-19. Four of the six patients also demonstrated failure of other organ systems, including cardiovascular and kidney failure.

Pluristems PLX cells are allogeneic mesenchymal-like cells that have immunomodulatory properties, meaning they induce the immune systems natural regulatory T cells and M2 macrophages, the company explained in a previous release. The result could be the reversal of dangerous overactivation of the immune system. This would likely reduce the fatal symptoms of pneumonia and pneumonitis (general inflammation of lung tissue).

Previous preclinical findings regarding PLX cells revealed significant therapeutic effects in animal studies of pulmonary hypertension, lung fibrosis, acute kidney injury and gastrointestinal injury.

We are pleased with this initial outcome of the compassionate use program and committed to harnessing PLX cells for the benefit of patients and healthcare systems, Yanay said.

Read more:
Israeli COVID-19 treatment with 100% survival rate tested on US patient - The Jerusalem Post

→←